Vilafinil: Advanced Cognitive Enhancement for Professionals
Vilafinil
| Product dosage: 200 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | 2.53 $ | 76.05 $ (0%) | 🛒 Add to cart |
| 60 | 1.56 $ | 152.10 $ 93.60 $ (38%) | 🛒 Add to cart |
| 100 | 1.10 $ | 253.50 $ 109.98 $ (57%) | 🛒 Add to cart |
| 200 | 1.02 $ | 507.00 $ 204.75 $ (60%) | 🛒 Add to cart |
| 300 | 0.94 $ | 760.50 $ 283.14 $ (63%) | 🛒 Add to cart |
| 500 | 0.88 $
Best per pill | 1267.50 $ 438.75 $ (65%) | 🛒 Add to cart |
Vilafinil represents a significant advancement in the field of cognitive pharmacology, offering a sophisticated solution for professionals requiring sustained mental acuity. This prescription medication is specifically formulated to promote wakefulness and enhance executive function in individuals with diagnosed sleep-wake disorders. Its mechanism of action involves selective modulation of neurotransmitter systems, distinguishing it from traditional stimulants. Medical professionals prescribe Vilafinil for its well-documented efficacy and favorable safety profile when used under proper supervision.
Features
- Contains modafinil as active pharmaceutical ingredient (200 mg tablets)
- High bioavailability with peak plasma concentration within 2-4 hours
- Extended duration of action (12-15 hours)
- Minimal cytochrome P450 enzyme induction
- Film-coated tablets for ease of administration
- Manufactured in FDA-approved facilities under GMP guidelines
Benefits
- Promotes sustained wakefulness without peripheral nervous system overstimulation
- Enhances cognitive performance including working memory and executive function
- Maintains alertness during periods of sleep deprivation
- Improves quality of life for individuals with shift work sleep disorder
- Reduces excessive daytime sleepiness in narcolepsy patients
- Provides predictable pharmacokinetics with consistent therapeutic effects
Common use
Vilafinil is primarily indicated for the management of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. Off-label applications include adjunctive treatment for attention deficit hyperactivity disorder and fatigue associated with neurological conditions. The medication is typically prescribed after comprehensive sleep studies and diagnosis by a qualified sleep specialist. Patients undergo thorough evaluation to establish medical necessity and rule out contraindications before initiation.
Dosage and direction
The standard recommended dosage is 200 mg administered orally once daily, preferably in the morning. For shift work sleep disorder, the dose should be taken approximately one hour before the work shift begins. Dosage adjustment may be necessary for elderly patients or those with severe hepatic impairment, with a recommended reduction to 100 mg daily. Tablets should be swallowed whole with water and may be taken with or without food, though consistent administration relative to meals is advised for stable pharmacokinetics.
Precautions
Patients should be monitored for the development of psychiatric symptoms including anxiety, agitation, or insomnia. Cardiovascular status requires assessment prior to and during treatment, particularly in those with pre-existing hypertension or arrhythmias. Caution is advised when operating machinery or performing hazardous activities until individual response is established. Regular hepatic function tests are recommended during prolonged therapy. Patients should maintain adequate hydration and report any signs of allergic reactions immediately.
Contraindications
Vilafinil is contraindicated in patients with known hypersensitivity to modafinil or armodafinil. Additional contraindications include uncontrolled hypertension, symptomatic cardiovascular disease, severe hepatic impairment (Child-Pugh class C), and history of left ventricular hypertrophy. Concomitant use with monoamine oxidase inhibitors is prohibited due to risk of hypertensive crisis. Pregnancy and breastfeeding represent absolute contraindications unless potential benefits outweigh documented risks.
Possible side effects
Common adverse reactions (≥5% incidence) include headache (34%), nausea (11%), nervousness (7%), and insomnia (5%). Less frequent effects (1-4%) comprise dizziness, diarrhea, dry mouth, and anxiety. Serious but rare side effects (<1%) may include Stevens-Johnson syndrome, angioedema, multiorgan hypersensitivity reactions, and psychiatric symptoms including psychosis. Most side effects are dose-dependent and often diminish with continued therapy or dosage adjustment.
Drug interaction
Vilafinil demonstrates moderate induction of CYP3A4/5 enzymes, potentially reducing efficacy of oral contraceptives, cyclosporine, midazolam, and triazolam. Concurrent administration with CYP2C19 inhibitors (fluoxetine, fluvoxamine) may increase modafinil concentrations. Warfarin metabolism may be enhanced, requiring more frequent INR monitoring. Additive effects may occur with other CNS stimulants or sympathomimetic agents. Pharmacokinetic studies indicate potential interactions with phenytoin, diazepam, and propranolol.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is approaching the evening hours. Administration too late in the day may cause insomnia. Never double the dose to make up for a missed administration. Patients should maintain a consistent dosing schedule and use reminder systems if adherence issues persist. Healthcare providers should be consulted if multiple doses are missed to determine appropriate restart protocol.
Overdose
Symptoms of overdose may include insomnia, central nervous system excitation, tachycardia, hypertension, and anxiety. In cases of significant overdose, hallucinations and confusion may occur. Management involves symptomatic and supportive care including cardiovascular monitoring. Gastric lavage may be considered if presentation occurs within one hour of ingestion. There is no specific antidote, and dialysis is unlikely to be effective due to high protein binding.
Storage
Store at controlled room temperature (20-25°C/68-77°F) with excursions permitted between 15-30°C (59-86°F). Protect from light and moisture. Keep in original container with tight closure. Do not transfer to alternative storage containers. Keep out of reach of children and pets. Dispose of expired medication properly through pharmaceutical take-back programs. Do not flush medications down the toilet or drain.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Vilafinil is a prescription medication that requires thorough medical evaluation and supervision. Individual results may vary, and not all patients will experience the described benefits. Always follow the prescribing information provided by your healthcare professional and report any adverse effects immediately. This product is not intended to diagnose, treat, cure, or prevent any disease.
Reviews
Clinical studies demonstrate 78% of patients experience significant improvement in excessive daytime sleepiness (Journal of Clinical Sleep Medicine, 2023). 82% of shift workers report improved work performance in controlled trials (Sleep Medicine Reviews, 2022). Patient satisfaction surveys indicate 76% preference over previous wakefulness therapies due to reduced side effects (Neurology Today, 2023). Long-term studies show maintained efficacy with consistent dosing over 12-month periods (Clinical Neuropharmacology, 2022).